Nome |
# |
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION, file dfe4d22b-9eb7-bb0a-e053-d805fe0a78d9
|
1.008
|
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS, file dfe4d22b-7a4b-bb0a-e053-d805fe0a78d9
|
998
|
MESENCHYMAL STEM CELLS FROM CML PATIENTS REGULATE GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS ACTIVATION, file dfe4d22b-9088-bb0a-e053-d805fe0a78d9
|
932
|
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells, file dfe4d22a-4b55-bb0a-e053-d805fe0a78d9
|
46
|
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma, file dfe4d22a-4a5b-bb0a-e053-d805fe0a78d9
|
42
|
Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia, file dfe4d22d-3118-bb0a-e053-d805fe0a78d9
|
32
|
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis, file dfe4d22b-a228-bb0a-e053-d805fe0a78d9
|
31
|
The Role of New Technologies in Myeloproliferative Neoplasms, file dfe4d22b-ce08-bb0a-e053-d805fe0a78d9
|
31
|
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection, file 3681630c-365a-45fb-bb31-ac0e1d665a38
|
29
|
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project, file 025758fa-3e45-496c-9bde-36f4a30ef873
|
18
|
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients, file dfe4d227-7db0-bb0a-e053-d805fe0a78d9
|
18
|
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma, file dfe4d227-8548-bb0a-e053-d805fe0a78d9
|
17
|
Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: A single-centre cohort pilot study, file dfe4d22b-5699-bb0a-e053-d805fe0a78d9
|
17
|
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study, file dfe4d22b-cdfb-bb0a-e053-d805fe0a78d9
|
17
|
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection, file dfe4d22e-e46d-bb0a-e053-d805fe0a78d9
|
17
|
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma (Cell Death & Disease, (2019), 10, 10, (704), 10.1038/s41419-019-1959-5), file dfe4d22b-9c8c-bb0a-e053-d805fe0a78d9
|
16
|
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance, file b251340d-5551-4459-a5a2-42ad99400fac
|
15
|
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53, file dfe4d229-d55d-bb0a-e053-d805fe0a78d9
|
15
|
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents, file dfe4d22d-3cdf-bb0a-e053-d805fe0a78d9
|
15
|
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases, file 64b8d549-1c6a-4621-92bf-44c802f29b84
|
14
|
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting, file 8a5d94ae-0504-419c-acc4-2b2ac56044dd
|
14
|
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database, file f4baab77-9259-42ac-b52c-1882083402be
|
14
|
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3, file dfe4d22b-3d37-bb0a-e053-d805fe0a78d9
|
13
|
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis, file dfe4d22b-eba3-bb0a-e053-d805fe0a78d9
|
13
|
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence, file dfe4d22c-00cb-bb0a-e053-d805fe0a78d9
|
13
|
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes, file dfe4d22e-e42f-bb0a-e053-d805fe0a78d9
|
13
|
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome, file 76d6570a-32cb-49d9-b5f5-cd117d6f3694
|
12
|
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib, file dfe4d228-abfe-bb0a-e053-d805fe0a78d9
|
12
|
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis, file 326db130-8d82-4ffa-be97-9a62d59ef068
|
11
|
Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study, file dfe4d22b-bff2-bb0a-e053-d805fe0a78d9
|
11
|
Bone Marrow BCL2/IgH+ Cells at Diagnosis and Not FCGRIIIA Polymorphism Predict Response in Follicular Non-Hodgkin’s Lymphoma Patients Treated with Sequential CHOP and Rituximab, file 7f7a0c67-224d-49c9-bc7d-c2848286be4d
|
10
|
Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity
together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients, file dfe4d227-203f-bb0a-e053-d805fe0a78d9
|
10
|
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells, file c64cc785-9540-4c76-beba-e49ce2a3589f
|
9
|
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine, file c889383e-75bf-4e18-bb4d-3ec227cee410
|
9
|
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation, file dfe4d227-a503-bb0a-e053-d805fe0a78d9
|
9
|
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment, file 2c8b4f41-7f09-4ab6-88c6-f82d472d5913
|
8
|
TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment, file 41b38c14-6098-4682-8512-b78aeccc8a49
|
8
|
Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models, file 91b9367b-d6d4-475d-beb5-9454f06e969d
|
8
|
IGFBP-6 Alters Mesenchymal Stromal Cell Phenotype Driving Dasatinib Resistance in Chronic Myeloid Leukemia, file a659cecd-5b1e-4af9-b7d2-da5012d1d321
|
8
|
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes, file dfe4d22b-e265-bb0a-e053-d805fe0a78d9
|
8
|
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts, file 0e8a2260-fd42-4766-9be8-293de4089d03
|
7
|
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports, file 1199ddd1-ab6a-4637-b2d3-8c85c975dcfc
|
7
|
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases, file 13fed71d-a434-439f-a7b2-0d7d66eb034b
|
7
|
The Role of Inflammation and Inflammasome in Myeloproliferative Disease, file 27e45a47-a593-44eb-9ab4-9fab804cbb89
|
7
|
Hedgehog signaling pathways in multiple myeloma, file 3811a6bc-3f97-421f-aaf5-e69d999851d9
|
7
|
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma, file 389bc9c7-6350-462f-ab2d-e93414320047
|
7
|
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib, file 61040104-9d8c-4582-b4a0-cdb86480449b
|
7
|
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field, file 6674fd2a-1d66-493f-a062-6a9e59027748
|
7
|
Focus on Osteosclerotic Progression in Primary Myelofibrosis, file 88340a6b-6c09-4492-8de5-269eef98ebaa
|
7
|
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab, file a6f308de-c7fc-45be-adcd-2937a5d83933
|
7
|
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib, file adb4612f-0de7-415a-8e80-f3507c4bdbfc
|
7
|
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis, file bdbf06d1-b031-47e5-a571-d5794efb28e2
|
7
|
Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC), file dfe4d227-7a28-bb0a-e053-d805fe0a78d9
|
7
|
Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations, file dfe4d22c-0285-bb0a-e053-d805fe0a78d9
|
7
|
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens, file 1d425818-7a8b-4e75-9905-c38eda5550fc
|
6
|
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes, file 507d29cf-a62e-420b-8b6a-53e129973391
|
6
|
Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance, file 524e8236-b33f-4821-8792-fcbb76f12873
|
6
|
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology, file bdd927fb-7e32-4c1a-816b-da0758c86809
|
6
|
IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis, file c40789a4-f169-4eca-b81e-2e2653b2b300
|
6
|
Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?, file c42b5adf-390d-4e6d-a52c-cbfcb733867b
|
6
|
A case of high-risk AML in a patient with advanced systemic mastocytosis, file d660a4be-7a1d-4545-ae41-4f37e0a22f33
|
6
|
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib, file dfe4d22b-ef7d-bb0a-e053-d805fe0a78d9
|
6
|
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib, file dfe4d22c-027c-bb0a-e053-d805fe0a78d9
|
6
|
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling, file f36cfa9d-7a35-4b0c-8cfb-039a5b69c831
|
6
|
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the FIL MCL0208 trial, file fb645783-f4ac-49d4-afa0-6be81bd8d2fb
|
6
|
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives, file 0ac83219-f9ac-4807-815a-50bf6195ed29
|
5
|
Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome, file 51b74a15-17f2-45cf-8ac7-fda7a873093a
|
5
|
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients, file 7bf331f9-0701-473b-85ee-afea3a81dc9c
|
5
|
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis, file 93805351-566a-408f-84d6-90537385cb54
|
5
|
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data, file 994ee233-3cce-4ead-841a-385abd56772e
|
5
|
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future, file a3c900cd-74cd-4553-9f6a-a8828dda20c7
|
5
|
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study, file a9ae34fc-7580-4c64-a1ce-d4a9c3a41f12
|
5
|
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data, file b1c7f51b-92be-4a64-be67-147a886d654c
|
5
|
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial, file dfe4d22b-cfa9-bb0a-e053-d805fe0a78d9
|
5
|
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project, file dfe4d22c-013d-bb0a-e053-d805fe0a78d9
|
5
|
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients, file dfe4d22c-0278-bb0a-e053-d805fe0a78d9
|
5
|
Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview, file e816ea64-5d62-4832-93b9-10b7673e4df1
|
5
|
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice, file 05feff65-a46a-4835-8cce-9eb1121f6b5b
|
4
|
Management of polycythemia vera: A survey of treatment patterns in Italy, file 25d23100-3619-47d6-aa33-c6571fd1b59d
|
4
|
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib, file 33c8fd80-feed-46a8-8161-b7f6efd35f3b
|
4
|
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes, file a14b4afe-0dd9-48b1-b3ae-a9a7481daa7e
|
4
|
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE), file bd378ba6-ee6a-4a59-a0c8-03b0c3ce06cf
|
4
|
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA, file d54e8d0d-bb80-4a0a-8217-86d03758aca9
|
4
|
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study, file dfe4d22b-f3c9-bb0a-e053-d805fe0a78d9
|
4
|
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes, file dfe4d22c-027f-bb0a-e053-d805fe0a78d9
|
4
|
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis, file f805bffc-29ff-46dc-98ca-6c8b17faadfb
|
4
|
From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox, file 0bf0700d-17d2-42ef-a8eb-e1dd65cd93d1
|
3
|
Drug-related cutaneous adverse events in philadelphia chromosome-negative myeloproliferative neoplasms: A literature review, file 33b13bff-4d3b-4839-b3a1-e430d0141a7e
|
3
|
Endoscopic features of gastro-intestinal lymphomas: From diagnosis to follow-up, file 5ab6fce7-a968-4cba-bf08-004f0ca73454
|
3
|
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib, file 78640d56-d5f7-4006-89e1-b46a0921cef1
|
3
|
The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large b-cell lymphoma, file 7fa1753f-4209-4d95-ba34-fe514ff63c04
|
3
|
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: An ex-vivo study, file 9036c550-7fb5-40d7-afea-9ce4c1dd7f49
|
3
|
Proteasome inhibitors as a possible therapy for SARS-CoV-2, file aba9d9c1-3569-4e30-9c5f-839759b773e0
|
3
|
Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?, file bc0856b2-cd47-4503-8e93-669ce3a3ae84
|
3
|
Monocytic myeloid derived suppressor cells in hematological malignancies, file d96c5852-1343-49fc-9000-25c39fc2e4d5
|
3
|
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint, file dfe4d227-4852-bb0a-e053-d805fe0a78d9
|
3
|
IGFBP-6: At the Crossroads of Immunity, Tissue Repair and Fibrosis, file e01c7bf6-c556-4962-8110-196838e6cdd6
|
3
|
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters, file ec27267e-e908-4876-9f63-ce3c047f737a
|
3
|
SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience, file f875096b-f978-42ba-8c71-6271b4e10e1a
|
3
|
Transient Leukemoid Reaction from T-Cell Large Granular Lymphocytes Post Autologous Stem Cell Transplant in a Patient Affected by Hodgkin Lymphoma, file 0c64b104-7e34-49ef-a059-368e9771f0bc
|
2
|
Totale |
3.842 |